🧠 Alzheimer's Disease Therapeutic Vaccine Tracker

Updated July 2026. Active field: At least 9 Alzheimer's vaccine candidates are currently in clinical trials, with 6+ in Phase 2/2b. Notable 2025–2026 activity: UB-311 (Vaxxinity, Aβ1-14 peptide vaccine) — updated Phase 2a data (78-week Taiwan study, published EBioMedicine 2023, re-analyzed 2026) reported 97% antibody response rate maintained at 93% end-of-study, favorable safety, slight decrease in cortical amyloid PET burden, and delayed cognitive decline. FDA fast-track designation granted May 2022; Vaxxinity delisted from stock market May 2024, but development continues. ACI-24.060 (AC Immune / Takeda, liposome-based Aβ vaccine) — Phase 1/2 ABATE trial (NCT05462106) enrolled prodromal AD patients + Down syndrome cohort; interim data show positive immunogenicity at lowest dose with no safety concerns at 6 weeks; trial expected to complete 2026. Historical failures still shaping the field: AN1792 (meningoencephalitis), Affitope AD02 and ACC-001 (no clinical effect), original ACI-24 (poor immunogenicity), and CAD-106 (Phase 3 failure). The paradigm has shifted toward carefully designed T-helper type 2 responses avoiding pro-inflammatory Th1 responses and autoimmunity.

Comprehensive tracking of Alzheimer's disease therapeutic vaccine development targeting amyloid-beta plaques, tau protein tangles, and neuroinflammation. Alzheimer's affects 7 million Americans, 55 million globally. Immunotherapy approaches aim to slow cognitive decline by clearing pathological proteins. Multiple Phase 2/3 trials underway targeting Alzheimer's pathology. Active and passive immunization strategies show promise but face safety challenges after early failures (AN1792).

⚠️ MAJOR UNMET MEDICAL NEED:

Alzheimer's disease affects 7 million Americans, 55 million globally. Leading cause of dementia and 6th leading cause of death in US. $345 billion annual cost in US alone. No disease-modifying treatments available - current drugs only temporarily manage symptoms. Therapeutic vaccines represent hope for slowing/preventing cognitive decline.

🔬 Clinical Trial & News Resources:

📊 View all Alzheimer's vaccine trials →
🌍 NIA Alzheimer's Information →
🌍 Alzheimer's Association →
📰 Latest News (Google) →

Alzheimer's Vaccines by Development Phase

US Cases (55M Globally)

$345B

Annual US Cost

Vaccines in Development

🔬 Phase 3 Clinical Trial

AADvac1 (Tau Vaccine)

Active immunotherapy targeting tau protein - Most advanced

Phase 3

Developer Axon Neuroscience

Target Pathological tau protein

Phase 2 Results Safe, reduced tau pathology

Trial Status ADAMANT Phase 3 ongoing

Developer: Axon Neuroscience | Trials: ClinicalTrials.gov Phase 3

Details: AADvac1 is first tau-targeted vaccine in Phase 3. Synthetic peptide vaccine inducing antibodies against pathological tau (misfolded, phosphorylated). Unlike amyloid-beta approach, tau pathology correlates better with cognitive decline. Phase 2 (ADAMANT study, 196 patients) showed excellent safety, high antibody response rates (>90%), reduced tau pathology biomarkers (CSF p-tau decline), slowed cognitive decline trend. Phase 3 ADAMANT trial enrolling ~500 mild Alzheimer's patients. Monthly injections for 2+ years. Primary endpoint: cognitive function (ADAS-Cog). Secondary: brain atrophy, tau PET imaging. Results expected 2025-2026. If successful, could be first approved Alzheimer's therapeutic vaccine.

🧬 Phase 2 Clinical Trials

UB-311 (Amyloid-Beta Vaccine)

Active immunization against Aβ with improved safety

Phase 2

Developer United Neuroscience/Vaxxinity

Target Amyloid-beta (Aβ1-14)

Phase 1/2a Results Safe, good antibody response

Developer: Vaxxinity (formerly United Neuroscience)

Description: UB-311 synthetic peptide vaccine targeting N-terminal Aβ (amino acids 1-14) linked to carrier protein. Designed to avoid T-cell activation that caused meningoencephalitis in AN1792. Phase 1/2a showed safety, robust antibody responses, biomarker improvements (CSF Aβ42 increase). Phase 2b ongoing in mild Alzheimer's. Subcutaneous injection every 3 months. Aims for disease-modifying effect by clearing amyloid plaques.

ACI-24 (Beta-Amyloid Liposome Vaccine)

Liposomal Aβ vaccine - Novel delivery

Phase 2

Developer AC Immune

Technology Aβ1-15 in liposomes

Phase 1b Results Safe, promising biomarkers

Developer: AC Immune | Partner: Janssen (J&J)

Description: ACI-24 Aβ1-15 peptide formulated in liposomes as adjuvant. Targets amyloid aggregates. Phase 1b (prodromal/mild AD) showed good safety, antibody responses, CSF biomarker improvements. Phase 2 evaluating efficacy. Quarterly injections. Partnership with Janssen accelerating development.

🧪 Phase 1 & Preclinical Development

Phase 1 Candidates (3)

Next-generation approaches

Phase 1

Candidates: (1) Lu AF20513 (Lundbeck) - Active Aβ vaccine with novel adjuvant; (2) ACI-35 (AC Immune/Eli Lilly) - Tau vaccine targeting pS396/pS404; (3) DNA vaccine platforms - Plasmid DNA encoding Aβ/tau epitopes.

Preclinical Platforms (4)

Novel immunotherapy strategies

Preclinical

Approaches: (1) mRNA vaccines - Encoding Aβ/tau antigens for immune response; (2) Nanoparticle vaccines - Enhanced antigen delivery to immune cells; (3) Combination vaccines - Targeting both Aβ AND tau simultaneously; (4) Anti-inflammatory vaccines - Targeting neuroinflammation (TNF-α, IL-1β).

Institutions: NIH/NIA, University of Pennsylvania, UC Irvine, Karolinska Institute

⚠️ Discontinued/Failed Programs - Learning from Setbacks

AN1792 & Bapineuzumab

First-generation failures - Critical lessons

Discontinued

AN1792 (Elan/Wyeth): First Aβ vaccine. Phase 2 halted 2002 after 6% developed meningoencephalitis (brain inflammation from T-cell activation). Despite termination, long-term follow-up showed plaque reduction in responders but NO cognitive benefit. Key lesson: Avoid T-cell epitopes, target B-cell responses only.

Bapineuzumab (Passive Immunization): Monoclonal antibody based on AN1792 approach. Phase 3 failed - no efficacy, vasogenic edema (ARIA-E) in ApoE4 carriers. Reinforced challenges of amyloid hypothesis.

📊 Disease Burden & Future Outlook

Alzheimer's Disease Burden: 7 million Americans, 55 million globally. Projected to reach 13 million US cases by 2050. Leading cause of dementia (60-80% of cases). 6th leading cause of death in US. $345 billion annual US cost (projected $1 trillion by 2050). No cure available - current drugs (cholinesterase inhibitors, memantine) only manage symptoms temporarily. New anti-amyloid antibodies (aducanumab, lecanemab) show modest benefit but high cost, limited access, safety concerns (ARIA).

Therapeutic Vaccine Strategy: Active immunization aims for long-lasting immunity with less frequent dosing vs. passive antibodies requiring frequent infusions. Potential advantages: lower cost, better accessibility, sustained response. Challenges: safety (AN1792 lesson), efficacy (amyloid hypothesis questioned), timing (early intervention critical).

Future Directions: Tau vaccines most promising (better correlation with symptoms). Combination approaches (amyloid + tau). Precision medicine (biomarker-guided, genetic risk stratification). Prevention trials in pre-symptomatic stage. Success requires understanding disease heterogeneity, patient selection, appropriate endpoints.